The global acute myeloid leukaemia market is estimated to grow at a CAGR of 13% in the first half of the forecast period. In 2018, the chemotherapy segment held 32% share of the global acute myeloid leukaemia market.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 149-page report you will receive 143 charts– all unavailable elsewhere.
The 149-page report provides clear detailed insight into the acute myeloid leukaemia market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Acute Myeloid Leukaemia Market forecast to 2029
• Forecast of the Global Acute Myeloid Leukaemia market by Treatment Type and Product Type: • Chemotherapy: Cytarabine, Daunorubicin, Others • Targeted Therapy: Midostaurin, Enasidenib, Others
• This report provides individual revenue forecasts to 2029 for these regional and national markets: • North America: US, Canada, and Mexico • Europe: Germany, France, United Kingdom, Italy, Spain and rest of Europe • Asia-Pacific: Japan, China, India, Australia and Rest of Asia-Pacific • LAMEA: GCC, Brazil, South Africa, Rest of LAMEA
Each national market forecast is further segmented by type: chemotherapy and targeted therapy.
• Our study discusses the selected leading companies that are the major players in the acute myeloid leukaemia market: • Bristol-Myers Squibb Company • Celgene • Clavis Pharma ASA • Daiichi Sankyo • Eisai • GSK • Novartis • Roche • Sunesis Pharmaceuticals • Teva
• This report discusses factors that drive and restrain the acute myeloid leukaemia market. This report also discusses the opportunities that can be tapped in this market.
• This report discusses Porter’s Five Forces analysis of the acute myeloid leukaemia market.
• This report also discusses several new agents that are in development for the treatment of acute myeloid leukaemia.
• Key questions answered in this report: • How is the Acute myeloid leukemia market evolving? • What are the drivers and restraints for the growth of the acute myeloid leukemia market? • What are the market shares of each segment of the overall acute myeloid leukemia market in 2019? • How will each acute myeloid leukemia submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2029? • How will the market shares for each acute myeloid leukemia submarket develop from 2019 to 2029? • What is the value of the leading acute myeloid leukemia segments in important regions of the world? • What will be the main driver for the overall market from 2019 to 2029? • How will political and regulatory factors influence the regional markets and submarkets? • How will the market shares of the national markets change by 2029 and which geographical region will lead the market by 2029? • Who are the leading players and what are their prospects over the forecast period? • How will the industry evolve during the period between 2019 and 2029?
Visiongain’s study is intended for anyone requiring commercial analyses for the acute myeloid leukaemia market. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview 1.1 Global Leukemia Market Overview 1.2 Market Definition and Scope 1.3 Why you should read this report? 1.4 How the report delivers? 1.5 Key Questions Answered in this Report 1.6 Who is the report for? 1.7 Report and Analysis Method 1.8 Frequently Asked Questions 1.9 Some Associated Reports 1.10 About Visiongain
2. Acute Myeloid Leukemia Market Overview 2.1 Introduction 2.1.1 French-American-British (FAB) classification 2.1.2 WHO Classification of AML 2.2 Epidemiology of AML 2.3 Treatment for AML 2.3.1 Medication Overview
3. Global Acute Myeloid Leukemia Market Forecast to 2029 – Based on Drug Type 3.1 Chemotherapy Based AML Therapeutics Market, 2019-2029 3.1.1 Cytarabine 3.1.2 Daunorubicin 3.1.3 Other Chemotherapy Drugs 3.2 Targeted therapy Market for AML Therapeutics – 2019-2029 3.2.1 Midostaurin 3.2.2 Enasidenib 3.2.3 Other targeted therapy 3.3 Other drugs used in the treatment of AML 4. Global AML Therapeutics Market Forecast to 2029 – Regional and National Market 4.1 North America AML Therapeutics Market Forecast, 2019-2029 4.1.1 USA AML Therapeutic Market Forecast, 2019-2029 4.1.2 Canada AML Therapeutic Market Forecast, 2019-2029 4.1.3 Mexico AML Therapeutic Market Forecast, 2019-2029 4.2 Europe AML Therapeutics Market Forecast, 2019-2029 4.2.1 Germany AML Therapeutics Market Forecast, 2019-2029 4.2.2 UK AML Therapeutics Market Forecast, 2019-2029 4.2.3 Italy AML therapeutics Market Forecast, 2019-2029 4.2.4 France AML Therapeutics Market Forecast, 2019-2029 4.2.5 Spain AML Therapeutics Market, 2019-2029 4.2.6 Rest of Europe AML Therapeutics Market Forecast, 2019-2029 4.3 Asia Pacific AML Therapeutics Market Forecast, 2019-2029 4.3.1 Japan AML Therapeutics Market Forecast, 2019-2029 4.3.2 China AML Therapeutics Market Forecast, 2019-2029 4.3.3 India AML Therapeutics Market Forecast, 2019-2029 4.3.4 Australia AML Therapeutics Market Forecast, 2019-2029 4.3.5 Rest of Asia Pacific AML Therapeutic Market Forecast, 2019-2029 4.4 Latin America and Middle East Africa AML Therapeutics Market Forecast, 2019-2029 4.4.1 GCC AML Therapeutics Market Forecast, 2019-2029 4.4.2 Brazil AML Therapeutics Market Forecast, 2019-2029 4.4.3 South Africa AML Therapeutics Market Forecast, 2019-2029 4.4.4 Rest of LAMEA AML Therapeutics Market, 2019-2029
5. Company Profiles 5.1 Daiichi Sankyo 5.1.1 Company Overview 5.1.2 Financial Overview 5.1.3 Recent Strategic Developments 5.2 Celgene Corporation 5.2.1 Company Overview 5.2.2 Operational Segments 5.2.3 Financial Overview 5.2.4 Recent Developments 5.3 Teva Pharmaceuticals 5.3.1 Company Profile 5.3.2 Operational Segments 5.3.3 Financial Highlights 5.3.4 Recent Developments 5.4 Eisai., Co. Ltd. 5.4.1 Company Overview 5.4.2 Operational Segments 5.4.3 Financial Overview 5.5 Novartis AG 5.5.1 Company Profile 5.5.2 Operational Segments 5.5.3 Financial Highlights 5.5.4 Recent Developments 5.6 GlaxoSmithKline Inc 5.6.1 Company Overview 5.6.2 Operating Segments 5.6.3 Financial Highlights 5.7 Sunesis Pharmaceuticals 5.7.1 Company Profile 5.7.2 Operational Segments 5.7.3 Financial Overview 5.8 Clavis Pharma ASA 5.8.1 Company Profile 5.9 F. Hoffman-La Roche Ltd. 5.9.1 Company Profile 5.9.2 Operational Segments 5.9.3 Financial Analysis 5.9.4 Recent Strategic Development 5.10 Bristol-Myers Squibb 5.10.1 Company Profile 5.10.2 Financial Overview
6. Acute Myeloid Leukemia: Qualitative Analysis 6.1. Market Drivers 6.1.1 The rise in Cases of Chronic Diseases 6.1.2 Research for Innovative Therapeutics 6.1.3 Increase in the geriatric population 6.2 Market Restraints 6.2.1 The adverse effect of the treatment 6.3 Market Opportunities 6.3.1 Unmet Oncological Demand 6.3.2 Untapped Opportunities in developing countries 7. Industry Analysis of the Market Players (Porter’s Five Force Analysis) 7.1 Bargaining Power of Suppliers 7.2 The threat of New Entrants 7.3 The threat of Substitute for Product 7.4 Bargaining Power of Buyers 7.5 Bargaining Power of Suppliers
Appendices Associated Reports Visiongain Report Sales Order Form About Visiongain Visiongain Report Evaluation Form
List of Tables Table 2.1 Global Acute Myeloid Leukemia, Subtypes, Based on FAB Classification Table 2.2 Global Acute Myeloid Leukemia, Subtypes, Based on WHO Classification Table 3.1. Global Acute Myeloid Leukemia Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 3.2. Global AML Therapeutics Market – Based on type (in %), 2018-2029 Table 3.3 Global AML Chemotherapy Drug Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 3.4. Cytarabine Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 3.5 Daunorubicin Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 3.6. Other Chemotherapy Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 3.7 Targeted Therapy Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 3.8 Midostaurin Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 3.9 Enasidenib Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 3.10 Other Targeted Therapy Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.1. North America AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Like the global perspective, the North American Chemotherapy market is expected to show a higher market share as compared to the Targetearket. Table 4.2 North America AML therapeutics Drug Market by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.3. USA AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.4. USA AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Table 4.5. USA AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.6. Canada AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.7. Canada AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.8. Mexico AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.9. Mexico AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.10. Europe AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.11. Europe AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.12 Germany AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.13 Germany AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.14 UK AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.15 UK AML Therapeutics Market by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.16 Italy AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.17. Italy AML Therapeutics Market Forecast by Type Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.18 France AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.19. France AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.20. Spain AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.21. Spain AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.22. Rest of Europe AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.23. ROE AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.24. Asia Pacific AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.25. Asia Pacific AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.26. Japan AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.27. Japan AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.28. China AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.29. China AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.30. India AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.31. India AML Therapeutics Market Forecast by Type: (Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.32. Australia AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.33. Australia AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.34. Rest of Asia Pacific AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.35. Rest of Asia Pacific AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.36. LAMEA AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.37. LAMEA AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.38. GCC AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.39. GCC AML Therapeutics Market by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.40. Brazil AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.41. Brazil AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.42. South Africa AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.43. South Africa AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.44. Rest of LAMEA AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 4.45. Rest of LAMEA AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029 Table 5.1 Daiichi Sankyo: Revenue ($m), R&D ($m), 2016-2018 Table 5.2 Daiichi Sankyo Recent Developments Table 5.3 Celgene: Revenue ($m), R&D ($m), 2016-2018 Table 5.4 Celgene Recent Developments Table 5.5 TEVA Operating Segments Table 5.6 TEVA: Revenue ($m), R&D ($m), 2016-2018 Table 5.7 TEVA Recent Developments Table 5.8 Eisai Operating Segments Table 5.9 Eisai Revenue ($m), R&D ($m), 2016-2018 Table 5.10 Novartis Operating Segments Table 5.11 Novartis: Revenue ($m), R&D ($m), 2016-2018 Table 5.12 Novartis Recent Developments Table 5.13 GSK Operating Segments Table 5.14 GSK: Revenue ($m), R&D ($m), 2016-2018 Table 5.15 Sunesis: Revenue ($m), R&D ($m), 2016-2018 Table 5.16 Roche Operating Segments Table 5.17 Roche: Revenue ($m), R&D ($m), 2016-2018 Table 5.18 Roche Recent Developments Table 5.19 Bristol-Myers: Revenue ($m), 2016-2018 Table 8.1 AML Drugs in the Pipeline: Agent, MOA, Clinical Trial Code Table 8.2 Completed Clinical Trials for AML Table 8.3 List of Recruiting Clinical Trials for AML Table 9.1: Global Acute Myeloid Leukemia Market by Treatment Type: Revenue ($m), 2019, 2023, 2029
List of Figures Figure 2.1 Percentage of estimated new Leukemia cases in 2018 among all blood cancer cases, a global perspective Figure 2.2 Prevalence of Acute Myeloid Leukemia in the population based on age (2018) Figure 3.1. Global Acute Myeloid Leukemia Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 3.2. Global AML Therapeutics Market (% Share) – Based on Type, 2018 Figure 3.3 Global AML Chemotherapy Drug Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 3.4. Global AML Chemotherapy Drugs (% Share) – Based on types 2018 Figure 3.5. Cytarabine Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 3.6 Daunorubicin Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 3.7. Other Chemotherapy Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 3.8. Targeted Therapy Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 3.9. Midostaurin Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 3.10 Enasidenib Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 3.11 Other Targeted Therapy Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.1. Global Percentage Share of AML Therapeutics Market by Region: % Share, 2019 Figure 4.2. Global Percentage Share of AML Therapeutics Market by Region: % Share, 2023 Figure 4.3. Global Percentage Share of AML Therapeutics Market by Region: % Share, 2029 Figure 4.4. North America AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.5 North America AML Therapeutics Market by Country: % Share, 2019 Figure 4.6. USA AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029 Figure 4.7. Canada AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.8. Canada AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029 Figure 4.9. Mexico AML therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.10 Mexico AML therapeutic Market Forecast by Type: Revenue ($m), 2019-2029 Figure 4.11. Europe AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.12. Europe AML Therapeutics Market by Region: % Share, 2019 Figure 4.13. Germany AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.14 Germany AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029 Figure 4.15. UK AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.16 UK AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029 Figure 4.17. Italy AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.18. Italy AML Therapeutics Market Forecast: Revenue ($m), 2019-2029 Figure 4.19 France AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.20. France AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029 Figure 4.21 Spain AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.22. Spain AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029 Figure 4.23. Rest of Europe AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.24. ROE AML Therapeutics Market by Type: Revenue ($m), 2019-2029 Figure 4.25. Asia Pacific AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.26. Asia Pacific AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029 Figure 4.27. Asia Pacific AML Therapeutics Market by Country: % Share, 2019 Figure 4.28. Japan AML therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.29. Japan AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029 Figure 4.30. China AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.31. China AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029 Figure 4.32. India AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.33. India AML Therapeutics Market by Type: Revenue ($m), 2019-2029 Figure 4.34. Australia AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.35. Australia AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029 Figure 4.36. Rest of Asia Pacific AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.37. Rest of Asia Pacific AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029 Figure 4.38. LAMEA AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.39. LAMEA AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029 Figure 4.40 LAMEA AML Therapeutics Market by Country: % Share, 2019 Figure 4.41. GCC AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.42. GCC AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029 Figure 4.43 Brazil AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.44. Brazil AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029 Figure 4.45. South Africa AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.46. South Africa AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029 Figure 4.47. Rest of LAMEA AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 4.48. Rest of LAMEA AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029 Figure 9.1: Global Acute Myeloid Leukemia Market by Treatment Type: Revenue ($m), 2019, 2023, 2029
AbbVie Agios Pharmaceuticals, Inc. Ambit Biosciences Corporation Amgen Animas Corporation Astex B. Braun Melsungen AG Baxter, Becton, Dickinson and Company (BD) Bayer Boehringer Ingelheim Bristol-Myers Squibb Company (Bristol-Myers) Celator Pharmaceuticals, Inc. Celgene Clavis Pharma ASA (Clavis Pharma) Cyclacel Daiichi Pharmaceutical Daiichi Sankyo Eisai Co., Ltd. (Eisai) F. Hoffmann-La Roche Ltd. (Roche) Fresenius SE & Co. KGaA GlaxoSmithKline plc (GSK) GLOBOCAN Hospira Medtronic Moog Inc. NeoMed Norsk Hydro Novartis Onyx Pharmaceuticals Sankyo Seattle Genetics Smiths Group Plc., Sunesis Pharmaceuticals, Inc. (Sunesis) TEVA Pharmaceutical Industries Limited (TEVA)
List of Organizations Mentioned in the Report American Cancer Organization Baylor Scott and White Research Institute Benaroya Research Institute at Virginia Mason Beth Israel Deaconess Medical Center Breslin Cancer Center Center for Blood Disorders and Stem Cell Transplantation Charles A. Sammons Cancer Center Columbia University Medical Dana Farber Cancer Institute Duke Cancer Center European Commission Fred Hutchinson Cancer Research Center Health Canada Herbert Irving Comprehensive Cancer Center Institute of Hematology & Blood Diseases Hospital,Tianjin James Graham Brown Cancer Center Legacy Emanuel Hospital & Health Center Mary Babb Randolph Cancer Center Massachusetts general Hospital Mayo Clinic MD Anderson Cancer Center Medical College of Wisconsin Cancer Center Medizinische Klinik und Poliklinik I Memorial Sloan Kettering Cancer Center Michigan State University Nantes University Hospital National Cancer Institute New Jersey Hematology Oncology Associates Northwestern University Ochsner Medical Center Penn State Hershey Cancer Institute-Clinical Trials Office Perelman Center for Advanced Medicine Princess Margaret Hospital St. Francis Cancer Center St. Joseph Mercy Hospital St. Vincent's Comprehensive Cancer Center Swedish Cancer Institute The Gayle and Tom Benson Cancer Center The University of Hong Kong The University of Iowa The University of Texas MD Anderson Cancer Center Thomas Jefferson University U.S. Food and Drug Administration (FDA) UCLA Medical Center, Division of Hematology/Oncology University Hospital, Caen University of Kansas Cancer Center University of Kansas Medical Center Research Institute University of Kentucky University of Louisville University of Michigan Health System University of Pennsylvania University of Texas M.D. Anderson Cancer Center VA Caribbean Healthcare System Weill Cornell Medical College Weill Medical College of Cornell University West Virginia University World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Global Acute Myeloid Leukaemia Market Forecast to 2029
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Conceptually, it is clear for all stakeholders in the health care segment as well in the biotechnological sector the benefits are evident since it will improve the speed and accuracy of diagnostics or analysis.
Visiongain Publishes Cell and Gene Supply Chain Services and Solutions Market Report 2020-2030
With the threat of growing number of patients due to the COVID-19 infections, the supply chain trends are looking at a shift with no contact and social distancing policies.
Visiongain Publishes Advanced Wound Care Market Report 2020-2030
Traditional wound care such as gauze and compression therapies are less effective than active wound care products. Active wound dressings create an environment more suitable for healing.
Visiongain Publishes Pregnancy Care Products Market Report 2020-2030
Advancement in development of organic pregnancy care products that are more safe and effective to improve physical appearance concerns such as stretchmark and sagging breasts and increase in awareness of the benefits of using these products through promotion of these products on social media platforms have increased the demand for pregnancy care products.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
